Korea Investment CORP Purchases 46,317 Shares of Edwards Lifesciences Corporation $EW

Korea Investment CORP increased its position in shares of Edwards Lifesciences Corporation (NYSE:EW) by 10.0% during the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 510,890 shares of the medical research company’s stock after buying an additional 46,317 shares during the quarter. Korea Investment CORP owned about 0.09% of Edwards Lifesciences worth $39,732,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in EW. Brighton Jones LLC bought a new position in shares of Edwards Lifesciences in the 4th quarter worth $266,000. Atlantic Union Bankshares Corp acquired a new stake in Edwards Lifesciences in the 2nd quarter valued at $40,000. Modera Wealth Management LLC bought a new stake in Edwards Lifesciences during the 2nd quarter valued at $221,000. Savant Capital LLC increased its stake in Edwards Lifesciences by 16.4% during the 2nd quarter. Savant Capital LLC now owns 25,842 shares of the medical research company’s stock valued at $2,021,000 after purchasing an additional 3,637 shares in the last quarter. Finally, AE Wealth Management LLC raised its holdings in Edwards Lifesciences by 1.4% during the second quarter. AE Wealth Management LLC now owns 91,755 shares of the medical research company’s stock worth $7,176,000 after buying an additional 1,253 shares during the last quarter. Institutional investors own 79.46% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on the stock. Evercore reaffirmed an “outperform” rating and issued a $94.00 price objective on shares of Edwards Lifesciences in a research note on Monday, January 5th. Citigroup restated a “buy” rating and issued a $101.00 target price (up from $96.00) on shares of Edwards Lifesciences in a report on Thursday, December 11th. Stifel Nicolaus set a $110.00 price target on shares of Edwards Lifesciences and gave the company a “buy” rating in a research report on Tuesday, January 20th. Barclays reiterated an “overweight” rating and set a $104.00 price target (up from $103.00) on shares of Edwards Lifesciences in a research note on Monday, January 12th. Finally, Wells Fargo & Company increased their price objective on Edwards Lifesciences from $96.00 to $100.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 11th. Three analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and nine have assigned a Hold rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $96.14.

Edwards Lifesciences Trading Up 3.2%

Shares of Edwards Lifesciences stock opened at $84.21 on Tuesday. The stock has a market capitalization of $48.91 billion, a P/E ratio of 46.02, a P/E/G ratio of 2.13 and a beta of 0.93. Edwards Lifesciences Corporation has a 52-week low of $65.94 and a 52-week high of $87.89. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.09 and a current ratio of 3.72. The stock’s 50-day simple moving average is $82.51 and its 200 day simple moving average is $81.49.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Tuesday, February 10th. The medical research company reported $0.58 earnings per share for the quarter, missing analysts’ consensus estimates of $0.62 by ($0.04). Edwards Lifesciences had a return on equity of 14.50% and a net margin of 17.69%.The business had revenue of $1.57 billion for the quarter, compared to the consensus estimate of $1.54 billion. During the same quarter in the prior year, the business earned $0.59 EPS. Edwards Lifesciences’s revenue for the quarter was up 13.3% compared to the same quarter last year. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. As a group, research analysts anticipate that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

Insider Activity at Edwards Lifesciences

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 1,019 shares of the stock in a transaction on Friday, January 9th. The stock was sold at an average price of $85.70, for a total transaction of $87,328.30. Following the sale, the vice president owned 22,002 shares in the company, valued at $1,885,571.40. This represents a 4.43% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, VP Donald E. Bobo, Jr. sold 24,000 shares of the firm’s stock in a transaction on Wednesday, February 25th. The stock was sold at an average price of $83.84, for a total value of $2,012,160.00. Following the completion of the transaction, the vice president directly owned 21,266 shares of the company’s stock, valued at $1,782,941.44. The trade was a 53.02% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 71,444 shares of company stock valued at $6,035,269. 0.34% of the stock is owned by insiders.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.